BAYRY Earnings Date: Nov 3, 2026 (Estimated) — Bayer AG
OTC · Healthcare · Drug Manufacturers - General
Updated
When is BAYRY's next earnings date?
Bayer AG (BAYRY) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 1:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.13 on revenue of $11.25B.
How did BAYRY do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Bayer AG posted EPS of $0.28 versus the $0.23 estimate, a beat of 20.0%. Revenue was $12.64B against a $12.31B estimate.
How much does BAYRY stock move after earnings?
BAYRY beat EPS estimates in 4 of its last 6 reported quarters.
About Bayer AG
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 0.23 | 0.28 | +20.00% | $12.64B | ✅ Beat | — | — | — |
| 2026-05-12 | Q1 2026 | 0.64 | 0.79 | +23.91% | $15.70B | ✅ Beat | — | — | — |
| 2026-03-04 | Q4 2025 | — | 0.18 | — | $13.32B | — | — | — | — |
| 2025-11-12 | Q3 2025 | — | 0.17 | — | $11.29B | — | — | — | — |
| 2025-08-06 | Q2 2025 | 0.24 | 0.35 | +45.83% | $12.18B | ✅ Beat | — | — | — |
| 2025-03-05 | Q4 2024 | 0.26 | 0.28 | +7.69% | $12.52B | ✅ Beat | +1.74% | -1.44% | -10.99% |
| 2024-11-12 | Q3 2024 | 0.17 | 0.07 | -58.82% | $10.96B | ❌ Miss | — | — | — |
| 2024-08-06 | Q2 2024 | 0.25 | 0.25 | +0.00% | $12.00B | ➖ Inline | — | — | — |
Showing last 8 quarters.